ASH 2022: Lymphoma

ASH Lymphoma eBook

Feb 21, 2023

Focus on ASH Lymphoma 2023v2.indd

Author

Rebecca Shover

View all posts

RETURN TO ASH Lymphoma eBook

MORE FROM ASH 2022: Lymphoma

High-Dose Chemotherapy Plus ASCT Superior to Standard Immune-Chemotherapy in Primary CNS Lymphoma

Dec 15, 2022

Ibrutinib Added to ASCT Improves Clinical Outcomes in Mantle Cell Lymphoma

Dec 15, 2022

Health and Safety Protocols

Dec 06, 2022

ASH Foundation Run & Walk

Dec 06, 2022

Friday Satellite Symposia

Dec 06, 2022

African American Patients with Diffuse Large B-Cell Lymphoma: Predictors of Inferior Survival

Nov 30, 2022

ASH 2022: Lymphoma

CAR-Hematotox Score Predicts Toxicity, Infection & Clinical Outcomes in MCL

Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had an increased risk for hematologic...

Metabolic Tumor Volume Predicts Response to Loncastuximab Tesirine in DLBCL

Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of Hematology to be a...

Odronextamab Scores in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising anti-tumor activity in heavily pre-treated patients with relapsed/refractory diffuse...

Follow Us

ASH 2022: Lymphoma

ASH Lymphoma eBook

Author

MORE FROM ASH 2022: Lymphoma

ASH 2022: Lymphoma

PW Weekly Newsletters

MORE FROM ASH 2022: Lymphoma

Stay connected to the latest news with Physician’s Weekly